Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

Exclusion Criteria

• •1. History or presence of clinically significant diseases.
• •2. Abnormal diet 4 weeks preceding the first dose of study medication.
• •3. Received any investigational product in a clinical study.
• •4. Previously been administered IMP in this study.
• •5. Taking any prescribed or OTC drug.
• •6. Taking moderate or strong inhibitors/inducers of cytochrome P450.
• •7. History of hypersensitivity to acetaminophen or similar chemical entities.
• •8. Presence or history of allergy or blood or plasma donation.
• •9. Blood or plasma donation
• •10. Smokers and those who have smoked within the last 12 months.
• •11. Current users of e-cigarettes and nicotine replacement products.
• •12. Consumption of prohibited beverages or foods.
• •13. Prior history of substance abuse or treatment.
• •14. Regular alcohol consumption.
• •15. Positive alcohol urine test at screening or admission.
• •16. Is a female with a positive pregnancy test result.
• •17. Positive urine screen for drugs of abuse.
• •18. Positive test for hepititus B or C, or HIV.
• •19. Active infection, periodontal disease,. certain dental appliances.
• •20. Glucose-6-phosphate-dehydrogenase (G6PD) deficiency.
• •21. Significant serious skin disease.
• •22. Cohort 3 only: history of cholecystectomy or gall stones.
• •23. Have poor venous access that limits phlebotomy
• •24. Evidence of current SARS-CoV-2 infection
• •25. Clinically significant abnormal clinical chemistry, hematology or urinalysis.
• •26. Immediate family members of a study site or Sponsor employee.
• •27. Failure to satisfy the Investigator of fitness to participate.